This was the stock's fourth consecutive day of gains.

Butter themed license plates? Listeria outbreak in nursing homes? $20M in frozen farmer funds released? Check out these ...

With a rising number of pet owners and increased spending, the pet industry is demonstrating strong growth potential.

Both of these metrics are at their most attractive levels in the company's history, making this a once-in-a-decade opportunity. Its discounted price combined with a long track record of steady growth, ...

Zoetis was granted a conditional license for its avian influenza vaccine for use in chickens. It's a step closer to fighting ...

This was the stock's third consecutive day of gains.

Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...

This new avian flu vaccine, developed by New Jersey-based Zoetis, was approved last week after meeting safety and efficacy standards.

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...

Q4 2024 Earnings Call Feb 13, 2025, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.